49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

  
26 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05666336
(ClinicalTrials.gov)
December 31, 20228/12/2022Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE PatientsProteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus ErythematosusSystemic Lupus ErythematosusBiological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: TacrolimusFen LiNULLNot yet recruiting18 Years75 YearsAll30Phase 4NULL
2NCT04702256
(ClinicalTrials.gov)
December 9, 202130/11/2020Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFInduction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFLupus Nephritis;Systemic Lupus Erythematosus (SLE)Drug: Obinutuzumab administration;Drug: Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil;Drug: Administration of methylprednisolone, paracetamol and dexchlorpheniramineAssistance Publique - Hôpitaux de ParisRoche Pharma AGRecruiting14 YearsN/AAll196Phase 3France
3ChiCTR2100048635
2021-07-192021-07-12The Impact of low-dose prednisone withdrawal on disease flare and organ damage in SLE patients: a randomized clinical trialThe Impact of low-dose prednisone withdrawal on disease flare and organ damage in SLE patients: a randomized clinical trial Systemic Lupus ErythematosusWithdrawal group:withdraw low dose prednisone;maintanence group:maintain low dose prednisone;Peking University First HospitalNULLPendingBothWithdrawal group:92;maintanence group:92;China
4ITMCTR1900002316
2019-06-202019-05-04Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusinStudy for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Systemic Lupus Erythematosushealthy control group:nothing;control group:Prednisone acetate tablets\Hydroxychloroquine;Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;Nanjing University of Chinese Medicine Affiliated HospitalNULLPendingBothhealthy control group:20;control group:20;Experimental group:20;Phase 1China
5ChiCTR1900022934
2019-06-202019-05-04Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusinStudy for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Systemic Lupus ErythematosusExperimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;control group:Prednisone acetate tablets?Hydroxychloroquine;healthy control group:nothing;Nanjing University of Chinese Medicine Affiliated HospitalNULLPendingBothExperimental group:20;control group:20;healthy control group:20;Phase 1China
6NCT03804723
(ClinicalTrials.gov)
June 201911/1/2019Glucocorticoids Withdrawal in Early Systemic Lupus ErythematosusGlucocorticoids Withdrawal in Early Systemic Lupus Erythematosus: a Randomized Placebo-controlled Equivalence TrialSystemic Lupus Erythematosus;Glucocorticoids;Therapy WithdrawalDrug: oral Prednisone 5mgUniversity of PisaNULLNot yet recruiting18 Years85 YearsAll321N/ANULL
7ChiCTR1800020286
2019-02-012018-12-22Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus erythematosusEfficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a clinical evaluation Systemic Lupus ErythematosusGroup 2:Langchuangjing granule + Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;Group 1:Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;Nanjing University of Chinese Medicine Affiliated HospitalNULLPendingBothGroup 2:40;Group 1:20;I (Phase 1 study)China
8ChiCTR1800017540
2018-09-012018-08-03A randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvementA randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvement systemic lupus erythematosus1:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day);2:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day) plus Mycophenolate Mofetil 500mg bid;Ruijin HospitalNULLCompleted1865Both1:65;2:65;Phase 4China
9NCT03492255
(ClinicalTrials.gov)
April 12, 201816/3/2018CYCLONES - CYClophosphamide LOw Dose and No Extra SteroidCYCLONES - CYClophosphamide LOw Dose and No Extra SteroidSystemic Lupus Erythematosus (SLE)Drug: Cyclophosphamide;Drug: Methylprednisolone;Drug: Prednisone;Drug: Mycophenolate MofetilUniversity of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloTerminated18 YearsN/AAll49N/ABrazil
10NCT03098823
(ClinicalTrials.gov)
September 12, 201721/3/2017A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLEA Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus ErythematosusLupus Erythematosus, Systemic;Lupus Erythematosus;FatigueDrug: RAYOS;Drug: PrednisoneAmpel BioSolutions, LLCNULLCompleted18 Years99 YearsAll62Phase 4United States
11ChiCTR-INR-17011495
2017-05-252017-05-26Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic syThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus Primary mild to moderate systemic systemic lupus erythematosusImmunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyNULLRecruitingBothImmunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;China
12NCT02558517
(ClinicalTrials.gov)
January 201422/9/2015Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic LupusEvaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic LupusSystemic Lupus ErythematosusDrug: prednisone discontinuationGroupe Hospitalier Pitie-SalpetriereNULLRecruiting18 Years75 YearsBoth136Phase 3France
13NCT01946880
(ClinicalTrials.gov)
November 20, 201313/9/2013Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus;SLEDrug: Mycophenolate Mofetil;Drug: Hydroxychloroquine or Chloroquine;Drug: PrednisoneNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.Terminated18 Years70 YearsAll102Phase 2United States
14EUCTR2009-017273-38-ES
(EUCTR)
26/10/201027/07/2010Estudio fase III, multicéntrico, aleatorizado, abierto de grupos paralelos para comparar la eficacia y seguridad de la pauta Prednisona-Ac Micofenólico-Ciclosporina a Prednisona-Ac Micofenólico en el tratamiento de las nefropatias lúpicas tipo III-IV-VEstudio fase III, multicéntrico, aleatorizado, abierto de grupos paralelos para comparar la eficacia y seguridad de la pauta Prednisona-Ac Micofenólico-Ciclosporina a Prednisona-Ac Micofenólico en el tratamiento de las nefropatias lúpicas tipo III-IV-V Nefritis lúpico tipo III,IV y V.
MedDRA version: 9;Level: LLT;Classification code 10029142;Term: Nephritis systemic lupus erythematosus
Product Name: Ciclosporina
Product Code: Csa
INN or Proposed INN: CICLOSPORINA
Other descriptive name: CICLOSPORIN
INN or Proposed INN: PREDNISONA
Other descriptive name: PREDNISONE
Product Name: Acido Micofenolico
Product Code: ACM
INN or Proposed INN: MICOFENOLICO ACIDO
Other descriptive name: MYCOPHENOLIC ACID
Manuel Praga TerenteNULLNot RecruitingFemale: yes
Male: yes
38Spain
15ChiCTR-TRC-12001935
2008-01-122012-02-12Effect of Detoxification, Removing Stasis and Nourishing Kidney Method on Promoting the Reduction of Prednisone in Treating SLEEffect of Detoxification, Removing Stasis and Nourishing Kidney Method on Promoting the Reduction of Prednisone in Treating SLE mild-to-moderate systemic lupus erythematosusTreatment Group:treated with prednisone and Jieduquyuzishen recipe;control group:treated with prednisone;Zhejinag University of Chinese MedicineNULLCompleted1860BothTreatment Group:161;control group:161;3 (Phase 3 study)China
16NCT00539838
(ClinicalTrials.gov)
December 19, 20073/10/2007A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Prednisone;Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate);Drug: Methylprednisolone;Drug: Ocrelizumab;Drug: PlaceboGenentech, Inc.Roche Pharma AGTerminated16 YearsN/AAll33Phase 3United States
17NCT00430677
(ClinicalTrials.gov)
June 20071/2/2007Efficacy and Safety Study of Abatacept to Treat Lupus NephritisA Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: Corticosteroids (prednisone or prednisolone);Drug: Abatacept;Drug: Mycophenolate mofetil (MMF)Bristol-Myers SquibbNULLTerminated18 YearsN/AAll423Phase 2/Phase 3United States;Argentina;Australia;Belgium;Brazil;Canada;China;France;Hong Kong;India;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Japan;Philippines;Puerto Rico
18EUCTR2006-002107-13-IT
(EUCTR)
24/11/200609/03/2007A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric-coated mycophenolate sodium myfortic in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - NDA randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric-coated mycophenolate sodium myfortic in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - ND Systemic lupus erythematosis
MedDRA version: 9.1;Level: LLT;Classification code 10042945;Term: Systemic lupus erythematosus
Trade Name: MYFORTIC*50CPR RIV 360MG
INN or Proposed INN: Mycophenolic acid
Trade Name: DELTACORTENE*20CPR 5MG
INN or Proposed INN: Prednisone
Trade Name: MYFORTIC*50CPR RIV 360MG
INN or Proposed INN: Mycophenolic acid
Trade Name: DELTACORTENE*20CPR 5MG
INN or Proposed INN: Prednisone
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
80Hungary;Germany;United Kingdom;France;Spain;Italy;Greece
19NCT00336414
(ClinicalTrials.gov)
June 200612/6/2006Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus NephritisFive-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intravenous CyclophosphamideSystemic Lupus Erythematosus NephritisDrug: cyclophosphamide-prednisone-azathioprineIstituto Giannina GasliniNULLWithdrawn1 Year18 YearsAll0Phase 3Italy
20EUCTR2005-003957-28-IT
(EUCTR)
02/05/200609/05/2006FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - NDFIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - ND New onset juvenile sistemic lupus erythematosus nephritis
MedDRA version: 6.1;Level: PT;Classification code 10025140
INN or Proposed INN: Azathioprine
INN or Proposed INN: Methylprednisolone
INN or Proposed INN: Prednisone
INN or Proposed INN: Cyclophosphamide
INN or Proposed INN: Cyclophosphamide
ISTITUTO GIANNINA GASLININULLNot RecruitingFemale: yes
Male: yes
141Phase 3Belgium;Denmark;Italy
21NCT00119678
(ClinicalTrials.gov)
September 200530/6/2005Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With PrednisoneA Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects With Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus FlaresSystemic Lupus ErythematosusDrug: Abatacept;Drug: Placebo;Drug: PrednisoneBristol-Myers SquibbNULLCompleted18 YearsN/AAll183Phase 2United States;Australia;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Korea, Republic of;Mexico;Puerto Rico;South Africa;Taiwan;United Kingdom;Sweden
22NCT00137969
(ClinicalTrials.gov)
May 10, 200526/8/2005A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus ErythematosusRandomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus ErythematosusLupus Erythematosus, SystemicDrug: Rituximab;Drug: Placebo;Drug: Prednisone;Drug: Acetaminophen;Drug: DiphenhydramineGenentech, Inc.NULLCompleted16 Years75 YearsAll262Phase 2/Phase 3United States;Canada
23NCT00006055
(ClinicalTrials.gov)
March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States
24NCT00000421
(ClinicalTrials.gov)
September 19973/11/1999Serologically Active, Clinically Stable Systemic Lupus ErythematosusSerologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: Prednisone;Drug: PlaceboNew York University School of MedicineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed13 Years65 YearsFemale154Phase 2United States
25NCT00001212
(ClinicalTrials.gov)
November 19863/11/1999Drug Therapy in Lupus NephropathyImmunosuppressive Drug Therapy in Membranous Lupus NephropathyNephrotic Syndrome;Systemic Lupus ErythematosusDrug: prednisone;Drug: cyclophosphamide;Drug: cyclosporin ANational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompletedN/AN/ABoth45Phase 2United States
26EUCTR2017-002050-36-FR
(EUCTR)
03/11/2017Personalised approach to the tapering of corticosteroid treatment in systemic lupus patientsPersonalised pharmacological approach to the tapering of corticosteroid doses in systemic lupus patients treated with prednisone - DECOR Systemic lupus erythematosus
MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Prednisone
Product Name: Prednisone
INN or Proposed INN: Prednisone
Other descriptive name: Prednisone
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNAFemale: yes
Male: yes
120Phase 4France